导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -4.32% | 3348/4773 |
| 近一周 | -3.45% | 4765/5465 |
| 近一月 | -3.43% | 2493/5421 |
| 近一季 | -2.81% | 1497/5231 |
| 近半年 | -5.83% | 3102/4920 |
| 近一年 | -5.55% | 3181/4394 |
| 近两年 | 25.06% | 2509/2954 |
| 近三年 | 7.40% | 1805/2253 |
| 成立以来 | 168.57% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.98% 2982/4961 |
1.33% 3044/5312 |
- - |
- - |
| 2025 | 7.05% 2937/4813 |
-0.78% 2404/3635 |
-2.29% 3338/4076 |
13.67% 2973/4524 |
-2.87% 3221/4813 |
| 2024 | 13.53% 1128/3463 |
3.64% 530/2808 |
-2.43% 1187/3014 |
18.82% 927/3129 |
-5.51% 2568/3463 |
| 2023 | -6.54% 856/2656 |
4.70% 885/2280 |
-4.73% 1270/2385 |
0.64% 357/2515 |
-6.90% 1969/2655 |
| 2022 | -16.98% 538/2207 |
-9.67% 333/1919 |
1.94% 1394/2016 |
-11.97% 617/2113 |
2.41% 944/2208 |
| 2021 | -4.48% 951/1822 |
0.94% 269/1255 |
-1.02% 1155/1330 |
-3.50% 644/1466 |
-0.93% 1286/1822 |
| 2020 | 26.08% 607/1250 |
-12.45% 886/1028 |
11.62% 722/1067 |
11.36% 457/1164 |
15.86% 188/1184 |
| 2019 | 51.46% 94/1092 |
34.88% 104/754 |
0.34% 175/804 |
0.17% 551/850 |
11.73% 48/918 |
| 2018 | -22.21% 233/834 |
- - |
- - |
- - |
-8.51% 95/691 |
| 2017 | 41.67% 24/714 |
- - |
- - |
- - |
- - |
| 2016 | -4.67% 161/605 |
- - |
- - |
- - |
- - |
| 2015 | 18.11% 130/575 |
- - |
- - |
- - |
- - |
| 2014 | 51.73% 70/237 |
- - |
- - |
- - |
- - |
| 2013 | -7.66% 128/186 |
- - |
- - |
- - |
- - |
| 2012 | 2.28% 99/140 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 建信深证基本面60ETF联接A VS. 长安沪深300非周期A(740101) |